HER2 vaccine study for high-risk breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have HER2-positive breast cancer that was high-risk, such as leftover cancer after chemo and HER2 therapy, or was stage 3 or inflammatory at diagnosis.
- You have finished at least 6 months of HER2-targeted therapy (like trastuzumab) and your last dose was within the last 6 months.
- You are in generally good health, able to perform daily activities, and have adequate heart, kidney, liver, and blood cell function.
- You are not pregnant and agree to use effective birth control during and for 6 months after treatment.
- You do not have other active cancers, serious autoimmune diseases, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.